Cerium AminoclayA Potential Hybrid Biomaterialfor Anticancer Therapy
2019
In this study, novel
biomedical properties of Ce-aminoclay (CeAC)
were investigated through in vitro and in vivo assays. CeAC (≥500
μg/mL) can selectively kill cancer cells (A549, Huh-1, AGS,
C33A, HCT116, and MCF-7 cells) while leaving most normal cells unharmed
(WI-38 and CCD-18Co cells). Notably, it displayed a high contrast
of simultaneous imaging in HeLa cells by blue photoluminescence without
any fluorescence dye. Its anticancer mechanism has been fully demonstrated
through apoptosis assays; herein CeAC induced high-level apoptosis
(16%), which promoted the expression of proapoptotic proteins (Bax,
p53, and caspase 9) in tumor cells. Besides, its biological behavior
was determined through antitumor effects using intravenous and intratumoral
administration routes in mice implanted with HCT116 cells. During
a 40 day trial, the tumor volume and tumor weight were reduced by
a maximum of 92.24 and 86.11%, respectively. The results indicate
that CeAC exhibits high bioavailability and therapeutic potential
based on its unique characteristics, including high antioxidant capacity
and electrostatic interaction between its amino functional groups
and the mucosal surface of cells. In summary, it is suggested that
CeAC, with its high bioimaging contrast, can be a promising anticancer
agent for future biomedical applications.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI